ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

THYMOGLOBULIN
Organ rejection prophylaxis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

THYMOGLOBULIN Rx

Generic Name and Formulations:
Anti-thymocyte globulin (rabbit) 25mg/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free; contains glycine, mannitol.

Company:
Sanofi Genzyme Company

Therapeutic Use:

Indications for THYMOGLOBULIN:

Prophylaxis and treatment of renal transplant acute rejection in conjunction with concomitant immunosuppression.

Adult:

Premedicate with corticosteroids, acetaminophen, and/or antihistamines 1 hour prior to each infusion. Give by IV infusion over 6 hours for first infusion into a high-flow vein, and over 4 hours on subsequent days of therapy. Prophylaxis: 1.5mg/kg once daily for 4–7 days; give first dose before reperfusion of the donor kidney. Treatment: 1.5mg/kg once daily for 7–14 days. WBC count 2000–3000 cells/mm3 or platelet count 50000–75000 cells/mm3: reduce dose by ½. WBC <2000 cells/mm3 or platelets <50000 cells/mm3: consider discontinuing therapy. When concomitant immunosuppressants: administer antifungal and antibacterial prophylaxis if clinically indicated. CMV-seropositive at the time of transplant or CMV-seronegative recipient from a CMV-seropositive donor: give antiviral prophylaxis. Consider decreasing maintenance immunosuppression therapy during Thymoglobulin use to avoid over-immunosuppression.

Children:

Not established.

Contraindications:

Acute or chronic infections.

Boxed Warning:

Immunosuppression.

Warnings/Precautions:

Should be used by experienced physicians in immunosuppressive therapy in transplantation. Must be administered under strict supervision in a hospital setting and monitored during the infusion. Have epinephrine (1:1000) and other resuscitative measures available. Discontinue immediately if anaphylaxis occurs. Risk of cytokine release syndrome (CRS) with rapid infusions; reduce infusion rates. Monitor for infections; treat with anti-infective therapy if appropriate. Increased risk of malignancies (eg, lymphoma, lymphoproliferative disorders). Monitor CBC, WBC, platelet, lymphocyte counts during and after treatment. Pregnancy; use effective contraception during and for at least 3 months after therapy. Nursing mothers: not recommended.

Pharmacological Class:

Immunosuppressant (gamma immune globulin).

Interactions:

Concomitant live vaccines: not recommended. May interfere with rabbit antibody-based immunoassays and cross-match or panel-reactive antibody cytotoxicity assays.

Adverse Reactions:

UTI, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, hyperkalemia, thrombocytopenia, leukopenia; serious immune-mediated reactions (eg, anaphylaxis, CRS), infusion-site reactions, infections.

How Supplied:

Single-use vial (10mL)—1


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs